Marshall & Sullivan’s AbbVie ABBV Stock Holding History

Marshall & Sullivan’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-133	Closed	-$24.7K	–	44
2025 Q2	$24.7K	Buy	+133	New	+$24.7K	0.01%	84
2018 Q3	–	Sell	-402	Closed	-$37.2K	–	47
2018 Q2	$37.2K	Buy	+402	New	+$39.3K	0.03%	64

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Marshall & Sullivan's ABBV Position: Q3 2025 in Review

Marshall & Sullivan sold out of AbbVie (ABBV) in Q3 2025, closing a stake of 133 shares — an estimated $24.7K sold.

Marshall & Sullivan first reported a position in ABBV in Q2 2018 and held it in 2 quarters. The position peaked at $37.2K in Q2 2018. 3,906 funds tracked by Wall St. Rank hold ABBV as of Q3 2025.

Marshall & Sullivan reported no remaining AbbVie position as of Q3 2025 after selling out during the quarter.
Marshall & Sullivan sold 133 AbbVie shares in Q3 2025, an estimated $24.7K.
Marshall & Sullivan first reported a position in AbbVie in Q2 2018 and held it in 2 quarters.
Marshall & Sullivan's AbbVie position peaked at $37.2K in Q2 2018.
3,906 funds tracked by Wall St. Rank held AbbVie as of Q3 2025.

Based on Marshall & Sullivan's 13F filing for Q3 2025, filed 15 Oct 2025.